High baseline levels of tumor necrosis factor receptor 1 are associated with progression of kidney disease in indigenous australians with diabetes: The eGFR follow-up study

Diabetes Care

Volumn 41, Issue 4, 2018, Pages 739-747

  Barr, Elizabeth L M ^a,b   Barzi, Federica ^a   Hughes, Jaquelyne T ^a,c   Jerums, George ^d,e   Hoy, Wendy E ^f   O'Dea, Kerin ^a,g   Jones, Graham R D ^h,i   Lawton, Paul D ^a   Brown, Alex D H ^g,j   Thomas, Mark ^k   Ekinci, Elif I ^a,d,e   Sinha, Ashim ^l   Cass, Alan ^e,m   MacIsaac, Richard J ^e,m   Maple Brown, Louise J ^c  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c ROYAL DARWIN HOSPITAL   (Australia)

^d Department of Endocrinology ^*  (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^h ST VINCENT S HOSPITAL   (Australia)

ⁱ UNIVERSITY OF NEW SOUTH WALES   (Australia)

^j DEPARTMENT OF HUMAN SERVICES   (Australia)

^k ROYAL PERTH HOSPITAL   (Australia)

^l CAIRNS BASE HOSPITAL   (Australia)

^m ST VINCENT S HOSPITAL   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TNFRSF1A PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADULT; AGED; ALBUMINURIA; AUSTRALIA; BLOOD; COMPLICATION; DIABETIC NEPHROPATHY; DISEASE EXACERBATION; EPIDEMIOLOGY; ETHNOLOGY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; LONGITUDINAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; POPULATION GROUP; RENAL REPLACEMENT THERAPY; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; ALBUMINURIA; AUSTRALIA; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POPULATION GROUPS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RENAL REPLACEMENT THERAPY;

EID: 85044525915     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc17-1919     Document Type: Article

References (39)

1. Kothari V, Galdo JA, Mathews ST. Hypoglycemic agents and potential anti-inflammatory activity. J Inflamm Res 2016;9:27-38
2. Koenig W. High-sensitivity C-reactive protein and atherosclerotic disease: From improved risk prediction to risk-guided therapy. Int J Cardiol 2013;168:5126-5134
3. Diamond JR. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int Suppl 1991;31:S29-S34
4. Amdur RL, Feldman HI, Gupta J, et al.; CRIC Study Investigators. Inflammation and progression of CKD: The CRIC Study. Clin J Am Soc Nephrol 2016;11:1546-1556
5. Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G; Cholesterol and Recurrent Events (CARE) Trial Investigators. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 2005;68:237-245
6. Fernández-Real JM, Vendrell J, Garcá I, Ricart W, Vall ès M. Structural damage in diabetic nephropathy is associated with TNF-a system activity. Acta Diabetol 2012;49:301-305
7. Pavkov ME, Weil EJ, Fufaa GD, et al. Tumor necrosis factor receptors 1 and 2 are associated with early glomerular lesions in type 2 diabetes. Kidney Int 2016;89:226-234
8. Gohda T, Niewczas MA, Ficociello LH, et al. Circulating TNF receptors 1 and 2 predict stage 3 CKDin type 1 diabetes. J Am Soc Nephrol 2012;23:516-524
9. Skupien J, Warram JH, Niewczas MA, et al. Synergism between circulating tumor necrosis factor receptor 2 and Hb A1c in determining renal decline during 5-18 years of follow-up in patients with type 1 diabetes and proteinuria. Diabetes Care 2014;37:2601-2608
10. Forsblom C, Moran J, Harjutsalo V, et al.; Finn Diane Study Group. Added value of soluble tumor necrosis factor-a receptor 1 as a biomarker of ESRD risk in patients with type 1 diabetes. Diabetes Care 2014;37:2334-2342
11. Krolewski AS, Niewczas MA, Skupien J, et al. Early progressive renal decline precedes the onset of microalbuminuria and its progression tomacroalbuminuria. Diabetes Care 2014;37:226-234
12. Niewczas MA, Gohda T, Skupien J, et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol 2012;23:507-515
13. Lee JE, Gohda T, Walker WH, et al. Risk of ESRD and all cause mortality in type 2 diabetes accorDing to circulating levels of FGF-23 and TNFR1. PLoS One 2013;8:e58007
14. Saulnier PJ, Gand E, Ragot S, etal.; SURDIAGENE Study Group. Association of serum concentration of TNFR1 with all-cause mortality in patients with type 2 diabetes and chronic kidney disease: Follow-up of the SURDIAGENE Cohort. Diabetes Care 2014;37:1425-1431
15. Pavkov ME, Nelson RG, Knowler WC, Cheng Y, Krolewski AS, Niewczas MA. Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes. Kidney Int 2015;87:812-819
16. Coca SG, Nadkarni GN, Huang Y, et al. Plasma biomarkers and kidney function decline in early and established diabetic kidney disease. J Am Soc Nephrol 2017;28:2786-2793
17. Shankar A, Sun L, Klein BE, et al. Markers of inflammation predict the long-term risk of developing chronic kidney disease: A population-based cohort study. Kidney Int 2011;80:1231-1238
18. Medenwald D, Girndt M, Loppnow H, et al. Inflammation and renal function after a four-year follow-up in subjects with unimpaired glomerular filtration rate: Results from the observational, population-based CARLA cohort. PLoS One 2014; 9:e108427
19. Carlsson AC, Nordquist L, Larsson TE, et al. Soluble tumor necrosis factor receptor 1 is associated with glomerular filtration rate progression and incidence of chronic kidney disease in two community-based cohorts of elderly individuals. Cardiorenal Med 2015;5:278-288
20. Liu G, Deng Y, Sun L, et al. Elevated plasma tumor necrosis factor-a receptor 2 and resistin are associated with increased incidence of kidney function decline in Chinese adults. Endocrine 2016;52:541-549
21. Schei J, Stefansson VT, Eriksen BO, et al. Association of TNF Receptor 2 and CRP with GFR decline in the general nondiabetic population. Clin J Am Soc Nephrol 2017;12:624-634
22. Australian Institute of Health and Welfare. Chronic Kidney Disease in Aboriginal and Torres Strait Islander People 2011. Cat. no. PHE 151. Canberra, AIHW, 2011
23. Hodge AM, Maple-Brown L, Cunningham J, et al. Abdominal obesity and other risk factors largely explain the high CRP in Indigenous Australians relative to the general population, but not gender differences: A cross-sectional study. BMC Public Health 2010;10:700
24. Maple-Brown LJ, Lawton PD, Hughes JT, et al. Study protocol-accurate assessment of kidney function in Indigenous Australians: Aims and methods of the e GFR Study. BMC Public Health 2010;10:80
25. Maple-Brown LJ, Hughes JT, Lawton PD, et al. Accurate assessment of kidney function in Indigenous Australians: The estimated GFR study. Am J Kidney Dis 2012;60:680-682
26. Maple-Brown LJ, Hughes JT, Ritte R, et al. Progression of kidney disease in Indigenous Australians: The e GFR Follow-up Study. Clin J Am Soc Nephrol 2016;11:993-1004
27. Hughes JT, Maple-Brown LJ, Thomas M, et al. Cross-sectional associations of albuminuria among Aboriginal and Torres Strait Islander adults: The e GFR Study. Nephrology (Carlton) 2018;23:37-45
28. Coresh J, Turin TC, Matsushita K, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 2014;311:2518-2531
29. Rebholz CM, Grams ME, Matsushita K, Selvin E, Coresh J. Change in novel filtration markers and risk of ESRD. Am J Kidney Dis 2015;66:47-54
30. Glantz S, Slinker B. Primer of Applied Regression and Analysis of Variance. New York, Mc Graw-Hill, 1990
31. Hasegawa G, Nakano K, Sawada M, et al. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 1991;40:1007-1012
32. Maple-Brown LJ, Ekinci EI, Hughes JT, et al.; investigators of the e GFR Study. Performance of formulas for estimating glomerular filtration rate in Indigenous Australians with and without type 2 diabetes: The e GFR Study. Diabet Med 2014;31:829-838
33. Agarwal R, Duffin KL, Laska DA, Voelker JR, Breyer MD, Mitchell PG. A prospective study of multiple protein biomarkers to predict progression in diabetic chronic kidney disease. Nephrol Dial Transplant 2014;29:2293-2302
34. Cachofeiro V, Goicochea M, de Vinuesa SG, Oubina P, Lahera V, Luno J. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl 2008;74:S4-S9
35. Macisaac RJ, Ekinci EI, Jerums G. Markers of and risk factors for the development and progression of diabetic kidney disease. Am J Kidney Dis 2014;63(Suppl. 2):S39-S62
36. Wu HY, Huang JW, Lin HJ, et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: Systematic review and bayesian network meta-analysis. BMJ 2013;347:f6008
37. Formentini I, Bobadilla M, Haefliger C, et al. Current drug development challenges in chronic kidney disease (CKD)-identification of individualized determinants of renal progression and premature cardiovascular disease (CVD). Nephrol Dial Transplant 2012;27(Suppl. 3):iii81-iii88
38. Deng J, Wu Q, Liao Y, Huo D, Yang Z. Effect of statins on chronic inflammation and nutrition status in renal dialysis patients: A systematic review and meta-analysis. Nephrology (Carlton) 2012;17:545-551
39. Elewa U, Sanchez-Nino MD, Martin-Cleary C, Fernandez-Fernandez B, Egido J, Ortiz A. Cardiovascular risk biomarkers in CKD: The inflammation link and the road less traveled. Int Urol Nephrol 2012;44:1731-1744